ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

Bullboard Posts

Post by retiredcopon Jul 30, 2018 5:17pm

200 Views

Post# 28387755

Selexis

This will cost us alot more to have this company manuafacture the PMN310, but when the potential new owner looks at it , they will be seeing the highest quality drugs available...well worth it in the end

Selexis SUREtechnology Platform™
Redefining best-in-class cell line development technology:
We believe that our technology offers solutions that no one else is able to provide. It's about QUALITY, SPEED, RELIABILITY, and INNOVATION. It's about being able to bring new and life-saving drugs to clinical trials and the patients who need them.
Selexis’ innovation and expertise have enabled the development and ongoing optimization of the most robust and flexible mammalian cell line-based protein expression platform in the industry. The SUREtechnology Platform improves the way that mammalian cells are used in the discovery, development, and manufacturing of any recombinant protein drug. This technology provides several key advantages over traditional approaches: Speed, Productivity, Stability, and Flexibility.
The Selexis team has been able to deploy SUREtechnology to generate nearly 80 clonal research cell banks that have reached clinical and commercial manufacturing, representing one of the industry’s largest portfolios.
Cell line development technologies to help develop and translate new therapies from the lab to the patient
Speed
250 stable CHO cell pools in 5 weeks for screening campaigns

High-expressing and stable research cell bank in 14 weeks from transfection

High yield

High and stable expression of recombinant protein therapeutic drug is enabled.
1-7 g/L for MAbs (fed-batch culture in shake flask)

Stability

> 90 days stable expression of the recombinant clonal cell lines expressing the therapeutic protein drugs
Not associated with gene amplifications (such as DHFR/MTX and GS/MSX)
Not associated with viral transduction or potential future infections

Flexibility

Enables the expression of any recombinant protein: no more expression bottlenecks (decreased attrition rate)
Highly effective in several mammalian cells (HEK-293, NS0, CHOs)

The SUREtechnology Platform is fueled by four major components, each of which is supported by a number of proprietary technologies that are unique to Selexis: